Загрузка...
Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment
BACKGROUND: Cholinesterase inhibitors (ChEIs) are an FDA-approved symptomatic treatment for patients with Alzheimer’s disease (AD). Its efficacy in patients with mild cognitive impairment (MCI), however, is controversial. Nonetheless, ChEIs have often been used in patients with MCI. From the perspec...
Сохранить в:
| Опубликовано в: : | Alzheimers Res Ther |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7786503/ https://ncbi.nlm.nih.gov/pubmed/33402198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00749-5 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|